William Balistreri
Pediatric Gastroenterology · Cincinnati, OHNPI 1952338378
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $166,679 of the $176,378 with a category attached, or 94.5%. Mirum Pharmaceuticals, Inc. accounts for 78.3% of it on its own, with 6 other manufacturers making up the rest. Among pediatric gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $1618.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirum Pharmaceuticals, Inc.$138K
- AstraZeneca$13K
- Gilead$12K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
- Ipsen Biopharmaceuticals, Inc$6K
- Biocodex, Inc.$816
- plus $1 from 1 others
Across 126 payments — averaging $3124.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$225K
- Merck$87K
- AbbVie$76K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
What the payments were for
- Consulting fees$166,67995%
- Speaking & faculty fees$5,7603%
- Travel & lodging$2,6872%
- Food & beverage$1,2511%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirum Pharmaceuticals, Inc. | 75 | $138,099 |
| AstraZeneca | 8 | $12,820 |
| Gilead | 14 | $11,632 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $7,250 |
| Ipsen Biopharmaceuticals, Inc | 2 | $5,760 |
| Biocodex, Inc. | 2 | $816 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$176,378 in reported general payments places this provider in the 95th percentile of 114 pediatric gastroenterology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LivmarliMaralixibat Chloride | 13 | $1,794,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mirum Pharmaceuticals, Inc.Livmarli | $138,099 | $1,794,71713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 pediatric gastroenterology providers in Ohio.
Other pediatric gastroenterology in Cincinnati
- James HeubiCincinnati$59K
- Ajay KaulCincinnati$31K
- Neha SantucciCincinnati$30K
- Akihiro AsaiCincinnati$30K
- Alexander MiethkeCincinnati$24K
- Vincent MukkadaCincinnati$24K
- Samuel KocoshisCincinnati$19K
- Khalil El-ChammasCincinnati$15K
- Jose GarzaCincinnati$13K
- Stephanie OliveiraCincinnati$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.